Allied Investment Advisors LLC Boosts Holdings in Medtronic PLC $MDT

Allied Investment Advisors LLC grew its holdings in Medtronic PLC (NYSE:MDT) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 124,806 shares of the medical technology company’s stock after acquiring an additional 6,614 shares during the period. Medtronic accounts for 1.9% of Allied Investment Advisors LLC’s portfolio, making the stock its 24th largest holding. Allied Investment Advisors LLC’s holdings in Medtronic were worth $11,887,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Delos Wealth Advisors LLC purchased a new position in shares of Medtronic during the 2nd quarter valued at about $27,000. Corundum Trust Company INC bought a new stake in Medtronic during the 3rd quarter worth approximately $27,000. Valley Wealth Managers Inc. bought a new stake in Medtronic during the 3rd quarter worth approximately $29,000. Steigerwald Gordon & Koch Inc. purchased a new position in Medtronic during the third quarter valued at approximately $33,000. Finally, Tripletail Wealth Management LLC bought a new position in shares of Medtronic in the third quarter worth approximately $34,000. Institutional investors own 82.06% of the company’s stock.

Medtronic Stock Up 1.9%

Shares of MDT opened at $102.96 on Monday. The business’s 50 day simple moving average is $99.60 and its 200-day simple moving average is $95.73. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. The stock has a market capitalization of $131.99 billion, a price-to-earnings ratio of 27.75, a price-to-earnings-growth ratio of 2.71 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The company had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the firm earned $1.26 earnings per share. Medtronic’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts expect that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Shareholders of record on Friday, December 26th were given a dividend of $0.71 per share. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.8%. Medtronic’s dividend payout ratio is 76.55%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on MDT shares. The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reissued a “hold” rating and set a $110.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Stifel Nicolaus upped their price objective on Medtronic from $90.00 to $105.00 and gave the stock a “hold” rating in a research note on Thursday, October 9th. Citigroup lifted their target price on Medtronic from $101.00 to $112.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th. Finally, Morgan Stanley increased their price objective on shares of Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a report on Wednesday, November 19th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).